In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolated from patients with cystic fibrosis

被引：0

作者：

Ruiz, Victor H. ^{[1
]}

Fratoni, Andrew ^{[1
]}

Nicolau, David P. ^{[1
,2
]}

Kuti, Joseph L. ^{[1
]}

机构：

[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA

[2] Hartford Hosp, Div Infect Dis, Hartford, CT USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2023年

关键词：

beta-lactam/beta-lactamase inhibitor; minimum inhibitory concentration; susceptibility; ANTIBIOTICS;

D O I：

10.1128/aac.00920-23

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Pseudomonas aeruginosa is a common multidrug-resistant pathogen in patients with cystic fibrosis (CF). The in vitro activity of imipenem/relebactam and imipenem was compared with other antipseudomonal antibiotics against 105 isolates from patients with CF from three US hospitals. Imipenem/relebactam, imipenem, meropenem, ceftazidime/avibactam, and ceftolozane/tazobactam susceptibilities were 77%, 55%, 58%, 90%, and 92%, respectively. Relebactam potentiates imipenem against CF P. aeruginosa by fourfold leading imipenem/relebactam to retain susceptibility against most isolates in this cohort.

引用

页数：4

共 16 条

[1]

AbdulWahab A, 2017, LUNG INDIA, V34, P527, DOI 10.4103/lungindia.lungindia_39_17

[2]

Asempa TE, 2019, J CLIN MICROBIOL, V57, DOI [10.1128/JCM.00535-19, 10.1128/jcm.00535-19]

[3] A Critical Evaluation of Newer β-Lactam Antibiotics for Treatment of Pseudomonas aeruginosa Infections [J].

Blomquist, Kathleen C. ;

Nix, David E. .

ANNALS OF PHARMACOTHERAPY, 2021, 55 (08) :1010-1024

[4]

Clinical and Laboratory Standards Institute (CLSI), 2022, M100-Performance standards for antimicrobial susceptibility testing

[5] Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin [J].

Ehsan, Zarmina ;

Clancy, John P. .

FUTURE MICROBIOLOGY, 2015, 10 (12) :1901-1912

[6] In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies) [J].

Hernandez-Garcia, Marta ;

Garcia-Castillo, Maria ;

Melo-Cristino, Jose ;

Pinto, Margarida F. ;

Goncalves, Elsa ;

Alves, Valquiria ;

Raquel Vieira, Ana ;

Ramalheira, Elmano ;

Sancho, Luisa ;

Diogo, Jose ;

Ferreira, Rui ;

Cruz, Hugo ;

Chaves, Catarina ;

Bou, German ;

Cercenado, Emilia ;

Delgado-Valverde, Mercedes ;

Oliver, Antonio ;

Pitart, Cristina ;

Rodriguez-Lozano, Jesus ;

Tormo, Nuria ;

Diaz-Reganon, Jazmin ;

Passaro, Leonor ;

Duarte, Joana ;

Canton, Rafael .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (11) :3163-3172

[7] In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020 [J].

Karlowsky, James A. ;

Lob, Sibylle H. ;

DeRyke, C. Andrew ;

Hilbert, David W. ;

Wong, Michael T. ;

Young, Katherine ;

Siddiqui, Fakhar ;

Motyl, Mary R. ;

Sahm, Daniel F. .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2022, 66 (05)

[8] Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City [J].

Lapuebla, Amabel ;

Abdallah, Marie ;

Olafisoye, Olawole ;

Cortes, Christopher ;

Urban, Carl ;

Landman, David ;

Quale, John .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (08) :5029-5031

[9] Contemporary analysis of ETEST for antibiotic susceptibility and minimum inhibitory concentration agreement against Pseudomonas aeruginosa from patients with cystic fibrosis [J].

Lasko, Maxwell J. ;

Huse, Holly K. ;

Nicolau, David P. ;

Kuti, Joseph L. .

ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2021, 20 (01)

[10] Cystic Fibrosis and Pseudomonas aeruginosa: the Host-Microbe Interface [J].

Malhotra, Sankalp ;

Hayes, Don, Jr. ;

Wozniak, Daniel J. .

CLINICAL MICROBIOLOGY REVIEWS, 2019, 32 (03)

← 1 2 →